SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
24 04 2019
Historique:
received: 29 12 2018
accepted: 07 04 2019
entrez: 25 4 2019
pubmed: 25 4 2019
medline: 17 8 2019
Statut: epublish

Résumé

Thousands of long noncoding RNAs (lncRNAs) are aberrantly expressed in various types of cancers, however our understanding of their role in the disease is still very limited. We applied RNAseq analysis from patient-derived data with validation in independent cohort of patients. We followed these studies with gene regulation analysis as well as experimental dissection of the role of the identified lncRNA by multiple in vitro and in vivo methods. We analyzed RNA-seq data from tumors of 456 CRC patients compared to normal samples, and identified SNHG15 as a potentially oncogenic lncRNA that encodes a snoRNA in one of its introns. The processed SNHG15 is overexpressed in CRC tumors and its expression is highly correlated with poor survival of patients. Interestingly, SNHG15 is more highly expressed in tumors with high levels of MYC expression, while MYC protein binds to two E-box motifs on SNHG15 sequence, indicating that SNHG15 transcription is directly regulated by the oncogene MYC. The depletion of SNHG15 by siRNA or CRISPR-Cas9 inhibits cell proliferation and invasion, decreases colony formation as well as the tumorigenic capacity of CRC cells, whereas its overexpression leads to opposite effects. Gene expression analysis performed upon SNHG15 inhibition showed changes in multiple relevant genes implicated in cancer progression, including MYC, NRAS, BAG3 or ERBB3. Several of these genes are functionally related to AIF, a protein that we found to specifically interact with SNHG15, suggesting that the SNHG15 acts, at least in part, by regulating the activity of AIF. Interestingly, ROS levels, which are directly regulated by AIF, show a significant reduction in SNHG15-depleted cells. Moreover, knockdown of SNHG15 increases the sensitiveness of the cells to 5-FU, while its overexpression renders them more resistant to the chemotherapeutic drug. Altogether, these results describe an important role of SNHG15 in promoting colon cancer and mediating drug resistance, suggesting its potential as prognostic marker and target for RNA-based therapies.

Sections du résumé

BACKGROUND
Thousands of long noncoding RNAs (lncRNAs) are aberrantly expressed in various types of cancers, however our understanding of their role in the disease is still very limited.
METHODS
We applied RNAseq analysis from patient-derived data with validation in independent cohort of patients. We followed these studies with gene regulation analysis as well as experimental dissection of the role of the identified lncRNA by multiple in vitro and in vivo methods.
RESULTS
We analyzed RNA-seq data from tumors of 456 CRC patients compared to normal samples, and identified SNHG15 as a potentially oncogenic lncRNA that encodes a snoRNA in one of its introns. The processed SNHG15 is overexpressed in CRC tumors and its expression is highly correlated with poor survival of patients. Interestingly, SNHG15 is more highly expressed in tumors with high levels of MYC expression, while MYC protein binds to two E-box motifs on SNHG15 sequence, indicating that SNHG15 transcription is directly regulated by the oncogene MYC. The depletion of SNHG15 by siRNA or CRISPR-Cas9 inhibits cell proliferation and invasion, decreases colony formation as well as the tumorigenic capacity of CRC cells, whereas its overexpression leads to opposite effects. Gene expression analysis performed upon SNHG15 inhibition showed changes in multiple relevant genes implicated in cancer progression, including MYC, NRAS, BAG3 or ERBB3. Several of these genes are functionally related to AIF, a protein that we found to specifically interact with SNHG15, suggesting that the SNHG15 acts, at least in part, by regulating the activity of AIF. Interestingly, ROS levels, which are directly regulated by AIF, show a significant reduction in SNHG15-depleted cells. Moreover, knockdown of SNHG15 increases the sensitiveness of the cells to 5-FU, while its overexpression renders them more resistant to the chemotherapeutic drug.
CONCLUSION
Altogether, these results describe an important role of SNHG15 in promoting colon cancer and mediating drug resistance, suggesting its potential as prognostic marker and target for RNA-based therapies.

Identifiants

pubmed: 31014355
doi: 10.1186/s13046-019-1169-0
pii: 10.1186/s13046-019-1169-0
pmc: PMC6480895
doi:

Substances chimiques

AIFM1 protein, human 0
Apoptosis Inducing Factor 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
RNA, Long Noncoding 0
RNA, Small Nucleolar 0
SNHG16 lncRNA, human 0
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

172

Subventions

Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : BFU2014-58027-R
Pays : International

Commentaires et corrections

Type : ErratumIn

Références

Tumour Biol. 2016 Apr;37(4):5591-7
pubmed: 26577854
Genes Dev. 2011 Sep 15;25(18):1915-27
pubmed: 21890647
Cell Death Differ. 2005 Nov;12(11):1445-8
pubmed: 15933737
J Cell Physiol. 2019 May;234(5):7032-7039
pubmed: 30317592
Int J Biochem Cell Biol. 2007;39(7-8):1337-42
pubmed: 17493862
J Transl Med. 2012 Oct 30;10:215
pubmed: 23110778
Front Genet. 2014 Mar 25;5:57
pubmed: 24723937
Oncotarget. 2017 Aug 18;8(48):84153-84167
pubmed: 29137412
J Cancer. 2017 Sep 15;8(16):3212-3225
pubmed: 29158793
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1594-1600
pubmed: 29217194
Methods Mol Biol. 2015;1206:87-95
pubmed: 25240889
Oncogene. 1996 Nov 21;13(10):2255-63
pubmed: 8950993
Tumour Biol. 2016 May;37(5):6801-12
pubmed: 26662309
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
J Biol Chem. 2005 Feb 25;280(8):6447-54
pubmed: 15590628
Cancer Lett. 2018 Jul 1;425:78-87
pubmed: 29604394
Nat Cell Biol. 2001 Sep;3(9):839-43
pubmed: 11533664
Cell Oncol (Dordr). 2015 Feb;38(1):17-28
pubmed: 25113790
Nature. 2012 Sep 6;489(7414):101-8
pubmed: 22955620
RNA. 2010 Aug;16(8):1478-87
pubmed: 20587619
Oncotarget. 2017 Mar 28;8(13):22187-22202
pubmed: 28108736
Mol Cancer. 2016 May 27;15(1):43
pubmed: 27233618
Oncotarget. 2016 Feb 2;7(5):5226-39
pubmed: 26637808
Oncogene. 2003 Oct 2;22(43):6669-78
pubmed: 14555980
Nat Genet. 2008 May;40(5):600-8
pubmed: 18372904
Oncogene. 2006 Mar 16;25(12):1763-74
pubmed: 16278674
Onco Targets Ther. 2016 Nov 30;9:7285-7295
pubmed: 27942222
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Oncol Rep. 2017 Nov;38(5):3265-3277
pubmed: 29048682
Biochem Biophys Res Commun. 2013 Oct 4;439(4):547-51
pubmed: 24036268
J Biol Chem. 2001 May 11;276(19):16391-8
pubmed: 11278689
Cancer Res. 2004 Jul 1;64(13):4569-76
pubmed: 15231668
Eur Rev Med Pharmacol Sci. 2016 May;20(9):1720-4
pubmed: 27212162
EMBO J. 2005 Aug 3;24(15):2815-26
pubmed: 16001080
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
EMBO J. 2005 Apr 6;24(7):1375-86
pubmed: 15775970
Genes Cancer. 2011 Mar;2(3):344-58
pubmed: 21779504
BMC Cancer. 2018 Aug 6;18(1):793
pubmed: 30081850
Mol Cell. 2015 May 7;58(3):440-52
pubmed: 25818646
J Biol Chem. 2008 May 23;283(21):14335-44
pubmed: 18326857
Adv Exp Med Biol. 2016;937:3-17
pubmed: 27573892
FEBS Lett. 2000 Jul 7;476(3):118-23
pubmed: 10913597
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29
pubmed: 16651366
Mol Cell Biol. 2004 Jul;24(13):5797-807
pubmed: 15199136
ChemMedChem. 2014 Sep;9(9):1932-56
pubmed: 24677606
J Biomed Sci. 2017 Jul 18;24(1):46
pubmed: 28720111
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718

Auteurs

Morvarid Saeinasab (M)

Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Industrial Biotechnology Reasearch Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

Ahmad Reza Bahrami (AR)

Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Industrial Biotechnology Reasearch Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

Jovanna González (J)

Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Institute of Health Research of Navarra (IdiSNA), Pamplona, Spain.

Francesco P Marchese (FP)

Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Institute of Health Research of Navarra (IdiSNA), Pamplona, Spain.

Dannys Martinez (D)

Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Institute of Health Research of Navarra (IdiSNA), Pamplona, Spain.

Seyed Javad Mowla (SJ)

Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Maryam M Matin (MM)

Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. matin@um.ac.ir.
Industrial Biotechnology Reasearch Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran. matin@um.ac.ir.

Maite Huarte (M)

Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. maitehuarte@unav.es.
Institute of Health Research of Navarra (IdiSNA), Pamplona, Spain. maitehuarte@unav.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH